Based on a systemic review and meta-analysis of 39 randomized controlled trials involving 60,580 patients, there is strong evidence indicating that SGLT2 inhibitors can increase the risk of DKA in individuals with T2DM compared to other antidiabetic drugs or placebos. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.